Another Drug Maker to Report Payments to Doctors

Posted by Jacob Goldstein in the Wall Street Journal Health Blog The pharma transparency bandwagon is filling up, as drug makers pile on to report their payments to physicians. Now GlaxoSmithKline has climbed aboard, the Financial Times reports . Besides publicly reporting what the company pays docs (presumably for things like consulting and giving speeches), Glaxo will also cap payments at $150,000 per year. Merck and Eli Lilly are among the companies that have already said they’ll make public at least some of their payments to doctors. Transparency could soon be forced on the whole industry, willing or unwilling: The Physician Payment Sunshine Act, sponsored by an influential senator, Chuck Grassley, would require drug and device makers to regularly report their payments to doctors.